Andrea Billé1, Lee M Krug2, Kaitlin M Woo3, Valerie W Rusch1, Marjorie G Zauderer4. 1. Thoracic Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA. 2. Thoracic Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA. 3. Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA. 4. Thoracic Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA. Electronic address: zauderem@mskcc.org.
Abstract
INTRODUCTION: Previous prognostic scoring systems for malignant pleural mesothelioma (MPM) included patients managed surgically and predated the use of pemetrexed. We analyzed prognostic factors in a contemporary cohort of patients with unresectable MPM who received pemetrexed-based chemotherapy. METHODS: This single-institution analysis included patients with MPM who were managed nonsurgically from 2000 to 2013. Variables correlated with overall survival (OS) included sex, performance status (PS), asbestos exposure, tumor laterality, histology, clinical stage, initial positron emission tomography maximum standardized uptake value, hemoglobin level, platelet count, lymphocyte count, white cell and neutrophil counts, treatment type, and clinical benefit from treatment. OS was analyzed by the Kaplan-Meier method, and significance (p < 0.05) of prognostic factors was analyzed by the log-rank test and Cox regression. RESULTS: A total of 191 patients met the study criteria: median age 71 years (range 46-90), 147 men (77%), 128 epithelioid tumors (67%), and 157 cases of stage III or IV MPM (82%). Median OS for all patients was 13.4 months. According to a univariate analysis, histology (p < 0.001), platelet count (< or = 450,000 versus >450,000, p < 0.001), initial PS (0-1 versus > or = 2), maximum standardized uptake value (< or = 8.1 versus >8.1, p = 0.037), and lymphocyte counts (p = 0.019) were associated with OS. According to a multivariable analysis, only histology, platelet count, and PS were independent prognostic factors. Epithelioid histology, PS, and elevated lymphocyte count at diagnosis were significantly associated with clinical benefit from first-line chemotherapy. CONCLUSIONS: Our results confirm the significance of elements of the Cancer and Leukemia Group B and European Organisation for Research and Treatment of Cancer prognostic scoring systems, identify factors associated with clinical benefit from chemotherapy, and emphasize the impact of histology and clinical benefit of chemotherapy on outcomes.
INTRODUCTION: Previous prognostic scoring systems for malignant pleural mesothelioma (MPM) included patients managed surgically and predated the use of pemetrexed. We analyzed prognostic factors in a contemporary cohort of patients with unresectable MPM who received pemetrexed-based chemotherapy. METHODS: This single-institution analysis included patients with MPM who were managed nonsurgically from 2000 to 2013. Variables correlated with overall survival (OS) included sex, performance status (PS), asbestos exposure, tumor laterality, histology, clinical stage, initial positron emission tomography maximum standardized uptake value, hemoglobin level, platelet count, lymphocyte count, white cell and neutrophil counts, treatment type, and clinical benefit from treatment. OS was analyzed by the Kaplan-Meier method, and significance (p < 0.05) of prognostic factors was analyzed by the log-rank test and Cox regression. RESULTS: A total of 191 patients met the study criteria: median age 71 years (range 46-90), 147 men (77%), 128 epithelioid tumors (67%), and 157 cases of stage III or IV MPM (82%). Median OS for all patients was 13.4 months. According to a univariate analysis, histology (p < 0.001), platelet count (< or = 450,000 versus >450,000, p < 0.001), initial PS (0-1 versus > or = 2), maximum standardized uptake value (< or = 8.1 versus >8.1, p = 0.037), and lymphocyte counts (p = 0.019) were associated with OS. According to a multivariable analysis, only histology, platelet count, and PS were independent prognostic factors. Epithelioid histology, PS, and elevated lymphocyte count at diagnosis were significantly associated with clinical benefit from first-line chemotherapy. CONCLUSIONS: Our results confirm the significance of elements of the Cancer and Leukemia Group B and European Organisation for Research and Treatment of Cancer prognostic scoring systems, identify factors associated with clinical benefit from chemotherapy, and emphasize the impact of histology and clinical benefit of chemotherapy on outcomes.
Authors: Anna K Nowak; Samuel G Armato; Giovanni Luca Ceresoli; Huseyin Yildirim; Roslyn J Francis Journal: Lung Cancer Date: 2010-06-11 Impact factor: 5.705
Authors: Kyuichi Kadota; Stefan S Kachala; Jun-Ichi Nitadori; Kei Suzuki; Mark P S Dunphy; Camelia S Sima; William D Travis; Valerie W Rusch; Prasad S Adusumilli Journal: J Thorac Oncol Date: 2012-07 Impact factor: 15.609
Authors: Jeremy J Erasmus; Mylene T Truong; W Roy Smythe; Reginald F Munden; Edith M Marom; David C Rice; Ara A Vaporciyan; Garrett L Walsh; Bradley S Sabloff; Lyle D Broemeling; Craig W Stevens; Katherine M Pisters; Donald A Podoloff; Homer A Macapinlac Journal: J Thorac Cardiovasc Surg Date: 2005-06 Impact factor: 5.209
Authors: Valerie W Rusch; Dorothy Giroux; Catherine Kennedy; Enrico Ruffini; Ayten K Cangir; David Rice; Harvey Pass; Hisao Asamura; David Waller; John Edwards; Walter Weder; Hans Hoffmann; Jan P van Meerbeeck Journal: J Thorac Oncol Date: 2012-11 Impact factor: 15.609
Authors: Raja M Flores; Timothy Akhurst; Mithat Gonen; Steven M Larson; Valerie W Rusch Journal: J Thorac Cardiovasc Surg Date: 2003-07 Impact factor: 5.209
Authors: G L Ceresoli; F Grosso; P A Zucali; M Mencoboni; G Pasello; C Ripa; D Degiovanni; M Simonelli; A Bruzzone; C Dipietrantonj; E Piccolini; G D Beretta; A G Favaretto; L Giordano; A Santoro; M Botta Journal: Br J Cancer Date: 2014-06-10 Impact factor: 7.640
Authors: Harvey I Pass; Dorothy Giroux; Catherine Kennedy; Enrico Ruffini; Ayten K Cangir; David Rice; Hisao Asamura; David Waller; John Edwards; Walter Weder; Hans Hoffmann; Jan P van Meerbeeck; Valerie W Rusch Journal: J Thorac Oncol Date: 2014-06 Impact factor: 15.609
Authors: Sara V Soldera; John Kavanagh; Melania Pintilie; Natasha B Leighl; Marc de Perrot; John Cho; Andrew Hope; Ronald Feld; Penelope A Bradbury Journal: Oncologist Date: 2018-11-26
Authors: Laura V Klotz; Michael Lindner; Martin E Eichhorn; Uwe Grützner; Ina Koch; Hauke Winter; Teresa Kauke; Thomas Duell; Rudolf A Hatz Journal: J Thorac Dis Date: 2019-05 Impact factor: 2.895